Navigation Links
$89 Million Proposed Class Action Settlement Provides Consumers and Insurers With Money Back for Celebrex and Bextra Purchases and Reimbursements
Date:4/29/2009

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- A federal court in San Francisco has granted preliminary approval to a proposed settlement with Pfizer Inc. ("Pfizer") about the marketing of the prescription drugs Bextra and Celebrex. The settlement in the case called In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-CV-01669, MDL No. 1699, pending in the United States District Court for the Northern District of California, will provide a Settlement Fund of $89 million to benefit a class of consumers and insurance companies or other entities (also called Third-Party Payors) that paid for either medicine before July 29, 2005.

The lawsuit, which does not concern safety risk of either drug, claims that Pfizer falsely advertised Bextra and Celebrex as having greater benefits than less expensive pain medications, causing consumers and other entities to pay a greater price for Bextra and Celebrex than they would otherwise have paid for less expensive alternatives or no medications at all. The lawsuit also claims that the advertising was not consistent with the drugs' Food and Drug Administration approved labeling. Pfizer denies any wrongdoing and denies all of the claims in the lawsuit but is settling this lawsuit to avoid the cost and expense of further litigation.

Consumers who paid for Bextra and/or Celebrex on or before July 29, 2005 are included in the Proposed Settlement. Third-Party Payors that paid or reimbursed for all or a percentage of the cost of Bextra and/or Celebrex on or before July 29, 2005 can also make a recovery under the Proposed Settlement. Third-Party Payors include insurance companies, union health and welfare plans, and self-insured employers.

Consumers and Third-Party Payors that wish to remain in the Settlement and file a claim will be bound by the Court's orders and will give up the right to sue the defendants on their own. Cla
'/>"/>

SOURCE Bextra and Celebrex Claims Administrator
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Registered Organ Donors Near Five Million, Save 300 Lives Since 2006
2. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
3. FSU researcher wins $2.2 million grant to study childhood obesity
4. UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa
5. Treatment Options Increase For Millions with Fibromyalgia
6. Attorney General Eric Holder Honors Florida Doctor and Announces $4.7 Million in Recovery Act Funds for State
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Working Towards Counting Malaria Out Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance
9. Millions of Youth Around the World Volunteer to Improve Communities
10. Proposed $350 Million Class Action Settlement Regarding Drug Pricing Provides Consumers and Third-Party Payors With Money Back
11. The Female Health Company / HLL Lifecare Limited Receive National AIDS Control Organization of India Order for 1.5 Million FC2 Female Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Market Research “Home Audio Equipment (Product Types - Home ... audio accessories) Market - Global Industry Analysis, Size, Share, ... was valued at USD 15.94 billion in 2012 and ... growing at a CAGR of 3.7% from 2013 to ...
(Date:8/21/2014)... 21, 2014 The Swedish-American Life ... conference will focus on the Future of Medicine ... innovation and commercialization. , With the mission to ... the worlds' of business and science. "Over the ... Summit, gathering a diverse community with representatives challenging ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... using sunscreen dropped nearly 12 percent in the last decade, ... the number of teens using indoor tanning beds barely decreased. ... risk of skin cancers, including deadly melanomas, the researchers noted. ... of teens who reported wearing sunscreen, from 67.7 percent in ...
(Date:8/21/2014)... August 21, 2014 The Onder Law ... product liability law, announces the launch of a new ... information on morcellator surgery lawsuits for cancer ... morcellator cancer warning and the July 2014 morcellator recall. ... April 17, 2014 FDA warning on morcellator surgery and ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... reporting successful application of the technology used in home ... make anticancer drugs like tamoxifen and paclitaxel dissolve more ... the disease. The process, described in ACS, journal, Langmuir, ... has potential for improving the performance of dyes, paints, ...
... PITTSBURGHUniversity of Pittsburgh researchers have recorded neuron activity ... biological root of the teenage propensity to consider ... more vulnerable to drug addiction, behavioral disorders, and ... the Journal of Neuroscience that electrode ...
... low socioeconomic status (SES) is associated with higher ... arthritis (RA). Statistically significant differences in race, public ... between depressed and non-depressed patients. Study findings are ... Care & Research , a journal published by ...
... 26 (HealthDay News) -- Hispanic seniors in the United ... be vaccinated against flu and pneumonia, a new study ... analyzed data from more than 244,000 seniors who took ... lifetime immunization rates for pneumonia were 74 percent for ...
... Staphylococcus aureus , the bacterium which is responsible for ... a strategy of hiding within host cells to escape ... The research, published by EMBO Molecular Medicine , ... their environmental conditions, lie dormant inside host cells and ...
... to 20 per cent of nurses and nursing students may ... tackling this difficult issue - and protecting public safety - ... message in a paper in the February issue of the ... recommended six key points that could be built into alternative-to-dismissal ...
Cached Medicine News:Health News:Pitt team finds teen brains over-process rewards, suggesting root of risky behavior, mental ills 2Health News:Low socioeconomic status increases depression risk in rheumatoid arthritis patients 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 3
(Date:8/21/2014)... 21, 2014  Vermillion, Inc. (NASDAQ: VRML ... and women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record ... for laboratory services companies. She has more than 20 ... where she held the position of Director, Lab Services ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Development, LLC (JRD) announced today that the U.S. Food ... designation to the supplemental New Drug Application (sNDA) filed ... an oral anticoagulant, to reduce the risk of thrombotic ... The FDA grants Priority Review to medicines ...
... Feb. 27, 2012 With cold and flu season ... American Pharmacists Association (APhA) encourages patients to actively ... medications. Pharmacists are the most accessible health care provider ... best over-the-counter (OTC) medication for cold, flu and allergy ...
Cached Medicine Technology:U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: